PROMAB

Founded in 2001., ProMab Biotechnologies develops and commercializes recombinant proteins, antibodies, and engineered cell lines through the integration of bioinformatics, molecular biology, protein expression, purification techniques, gene cloning, microbiology, and immunology, using novel high-throughput technologies. ProMab provides its proprietary proteins, engineered cell lines, and antibodies to deliver innovative research and diagnostic products, as well as services for the global biomedical research community through collaborations, partnerships, and joint ventures with other biotechnology and bio-reagent companies. ProMab has also developed a novel mRNA lipid nanoparticle (mRNA-LNP) platform for ready-to-use reagents and custom research services to advance the current offerings and expand to more fields of research. ProMab is on target to be one of the leading suppliers of bio-reagents in the twenty-first century and is committed to improving human health with a focus on the..

Also known as: ProMab Biotechnologies, Inc.

Primary location: Richmond United States